Canaccord Genuity Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Eyes on Launch Following DIFICID Approval
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $20.
Canaccord analyst Dr. George Farmer, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst Dr. George Farmer, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
